San Diego, CA (PRWEB) March 16, 2015
ACEA Biosciences, Inc., a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research, is pleased to announce Lincoln C. Muir as National Sales Director for the United States.
Lincoln Muir is a 25 year veteran of the Life Sciences Industry where he has held a number of commercial leadership positions in the drug discovery and medical research markets. Lincoln has a strong background in building and managing successful sales teams that are technology driven and highly specialized. Prior to joining ACEA Biosciences, Mr. Muir served as Director of Business Development for Genalyte, Inc., a San Diego based biotechnology company utilizing silicon photonics to develop multiplex assays for the detection of autoimmune disease, cancer, and immunogenicity to biological therapies. Prior to Genalyte Inc., Mr. Muir held roles at Corning and GE Healthcare managing highly technical sales teams that were responsible for high throughput, label-free screening technologies, and cellular analysis.
“Lincoln Muir is a wonderful addition to our commercial team,” stated Mike Honeysett, VP of Global Commercialization. “He is a terrific mentor who brings out the best in people and we are quite confident that the U.S. sales team will thrive under his leadership.”
“ACEA Biosciences has developed a culture focused on the customer by seeking to understand and then deliver innovative applications,” said Lincoln Muir. “A philosophy of cutting edge technologies combined with the concept of ‘ease of use’ and customer satisfaction drive the company at all levels of the organization. The quality and commitment of the team at ACEA represents a unique opportunity for customers and collaborators to drive the drug discovery process forward, and ultimately improve treatments for patients.”
About ACEA Biosciences
Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a privately held biotechnology company pioneering in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. With headquarters in San Diego, CA, ACEA has developed proprietary technology and launched its first product in 2004. Researchers are advancing their studies utilizing 1,300+ placed instruments for broad and diverse applications. The technology has been cited in over 600 peer-reviewed publications. ACEA’s xCELLigence® Real-Time Cell Analysis and NovoCyte™ Bench-Top Flow Cytometer Systems are used in pre-clinical drug discovery and development, toxicity, safety pharmacology, and basic academic research. Visit http://www.aceabio.com to learn more.
ACEA Biosciences, Inc.
6779 Mesa Ridge Road, Suite100
San Diego, California 92121
1-866-308-2232 Toll Free
Contact for Media Inquiries:
Leyna Zhao, Ph.D.
Global Marketing Manager
Michael Honeysett, MBA
Vice President of Global Commercialization